Skip to main content
Erschienen in: Journal of Neurology 9/2018

26.06.2018 | Original Communication

Beyond 35 years of Parkinson’s disease: a comprehensive clinical and instrumental assessment

verfasst von: Alberto Romagnolo, Margherita Fabbri, Aristide Merola, Elisa Montanaro, Sara Palermo, Tiziana Martone, Agostino Seresini, Stefano Goldwurm, Mario Giorgio Rizzone, Leonardo Lopiano

Erschienen in: Journal of Neurology | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

We sought to characterize the clinical, neuropsychological, electrophysiological, and neuroimaging features of Parkinson’s disease (PD) after over 35 years since the onset of motor symptoms.

Methods

Five consecutively consenting PD patients treated with subthalamic nucleus deep brain stimulation (STN-DBS) were recruited in a cross-sectional study of motor (Unified PD Rating Scale section-III), non-motor (Non-Motor Symptoms Scale), autonomic (Scale for Outcome in PD-Autonomic), and neuropsychological features associated with the very advanced phase of PD. In addition, patients underwent neurophysiological (autonomic tests and nerve conduction studies) and neuroimaging (brain MRI, 123I-FP-CIT SPECT, and 123I-MIBG myocardial scintigraphy) studies, as well as a genetic analysis of 34 genes and single nucleotide polymorphisms associated with PD.

Results

There was a sustained motor response to l-dopa (range 14.4–35.6%), STN-DBS (23.3–38.4%), and l-dopa plus STN-DBS (37.8–63.0%). There were mild-to-moderate non-motor symptoms (range 19–83 on a scale of 0 to 360) and autonomic dysfunction (8–28 on a scale of 0–69). Two patients were demented, one had mild cognitive impairment, and two were cognitively preserved. Three patients had a sensory-axonal peripheral neuropathy and two a moderate-to-severe autonomic neuropathy. All cases showed a complete nigro-striatal dopaminergic denervation and a severe cardiovascular noradrenergic denervation. The brain MRI revealed only moderate frontal atrophy. The genetic tests were unremarkable.

Conclusions

Even after more than 35 years of disease, L-dopa  and STN-DBS remain effective on PD cardinal symptoms. Although axial, autonomic, and neuropsychological features may become key determinants of disability, some patients maintain a satisfactory quality of life, without significant motor and non-motor impairment.
Literatur
1.
Zurück zum Zitat Berg D, Postuma RB, Bloem B et al (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29:454–462CrossRefPubMedPubMedCentral Berg D, Postuma RB, Bloem B et al (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29:454–462CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Bronstein JM, Tagliati M, Alterman RL et al (2011) Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 68:165–171CrossRefPubMed Bronstein JM, Tagliati M, Alterman RL et al (2011) Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 68:165–171CrossRefPubMed
3.
Zurück zum Zitat Devos D, French DUODOPA, Study Group (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 24:993–1000CrossRefPubMed Devos D, French DUODOPA, Study Group (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 24:993–1000CrossRefPubMed
4.
Zurück zum Zitat García Ruiz PJ, Sesar Ignacio A, Ares Pensado B et al (2008) Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord 23:1130–1136CrossRefPubMed García Ruiz PJ, Sesar Ignacio A, Ares Pensado B et al (2008) Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord 23:1130–1136CrossRefPubMed
5.
Zurück zum Zitat Rizzone MG, Fasano A, Daniele A et al (2014) Long-term outcome of subthalamic nucleus DBS in Parkinson’s disease: from the advanced phase towards the late stage of the disease? Parkinsonism Relat Disord 20:376–381CrossRefPubMed Rizzone MG, Fasano A, Daniele A et al (2014) Long-term outcome of subthalamic nucleus DBS in Parkinson’s disease: from the advanced phase towards the late stage of the disease? Parkinsonism Relat Disord 20:376–381CrossRefPubMed
6.
Zurück zum Zitat Merola A, Zibetti M, Angrisano S et al (2011) Parkinson’s disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. Brain 134:2074–2084CrossRefPubMed Merola A, Zibetti M, Angrisano S et al (2011) Parkinson’s disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. Brain 134:2074–2084CrossRefPubMed
7.
Zurück zum Zitat Munhoz RP, Espay AJ, Morgante F et al (2013) Long-duration Parkinson’s disease: role of lateralization of motor features. Parkinsonism Relat Disord 19:77–80CrossRefPubMed Munhoz RP, Espay AJ, Morgante F et al (2013) Long-duration Parkinson’s disease: role of lateralization of motor features. Parkinsonism Relat Disord 19:77–80CrossRefPubMed
8.
Zurück zum Zitat Pinter B, Diem-Zangerl A, Wenning GK et al (2015) Mortality in Parkinson’s disease: a 38-year follow-up study. Mov Disord 30:266–269CrossRefPubMed Pinter B, Diem-Zangerl A, Wenning GK et al (2015) Mortality in Parkinson’s disease: a 38-year follow-up study. Mov Disord 30:266–269CrossRefPubMed
9.
Zurück zum Zitat Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752CrossRefPubMedPubMedCentral Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Defer GL, Widner H, Marié RM et al (1999) Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 14:572–584CrossRefPubMed Defer GL, Widner H, Marié RM et al (1999) Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 14:572–584CrossRefPubMed
11.
Zurück zum Zitat Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease (2003) The unified Parkinson’s disease rating scale (UPDRS): status and recommendations. Mov Disord 18:738–750CrossRef Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease (2003) The unified Parkinson’s disease rating scale (UPDRS): status and recommendations. Mov Disord 18:738–750CrossRef
12.
Zurück zum Zitat Levy G, Louis ED, Cote L et al (2005) Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 62:467–472CrossRefPubMed Levy G, Louis ED, Cote L et al (2005) Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 62:467–472CrossRefPubMed
13.
Zurück zum Zitat Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911CrossRefPubMed Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911CrossRefPubMed
14.
Zurück zum Zitat Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson IML (eds) Third symposium on Parkinson’s disease. E & S Livingston, Edinburgh, pp 152–157 Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson IML (eds) Third symposium on Parkinson’s disease. E & S Livingston, Edinburgh, pp 152–157
15.
Zurück zum Zitat Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The Parkinson’s disease questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26:353–357CrossRefPubMed Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The Parkinson’s disease questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26:353–357CrossRefPubMed
16.
Zurück zum Zitat O’Neil KH, Purdy M, Falk J, Gallo L (1999) The dysphagia outcome and severity scale. Dysphagia 14:139–145CrossRefPubMed O’Neil KH, Purdy M, Falk J, Gallo L (1999) The dysphagia outcome and severity scale. Dysphagia 14:139–145CrossRefPubMed
17.
Zurück zum Zitat Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRefPubMed Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRefPubMed
18.
Zurück zum Zitat Merola A, Rizzi L, Artusi CA et al (2014) Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients. J Neurol 261:1745–1751CrossRefPubMed Merola A, Rizzi L, Artusi CA et al (2014) Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients. J Neurol 261:1745–1751CrossRefPubMed
19.
Zurück zum Zitat Beck AT (1987) Beck depression inventory. Psychological Corporation, San Antonio Beck AT (1987) Beck depression inventory. Psychological Corporation, San Antonio
20.
Zurück zum Zitat Spielberger CD, Gorsuch RL, Lushene RE (1970) Manual for the state-trait anxiety inventory. Consulting Psychologist Press, Palo Alto Spielberger CD, Gorsuch RL, Lushene RE (1970) Manual for the state-trait anxiety inventory. Consulting Psychologist Press, Palo Alto
21.
Zurück zum Zitat Marin RS (1991) Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 3:243–254CrossRefPubMed Marin RS (1991) Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 3:243–254CrossRefPubMed
22.
Zurück zum Zitat Litvan I, Goldman JG, Tröster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27:349–356CrossRefPubMedPubMedCentral Litvan I, Goldman JG, Tröster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27:349–356CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–1707CrossRefPubMed Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–1707CrossRefPubMed
24.
Zurück zum Zitat Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19:1306–1312CrossRefPubMed Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19:1306–1312CrossRefPubMed
25.
Zurück zum Zitat Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M (2006) EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 13:930–936CrossRefPubMed Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M (2006) EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 13:930–936CrossRefPubMed
26.
Zurück zum Zitat Boulton AJ, Vinik AI, Arezzo JC et al (2005) Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28:956–962CrossRefPubMed Boulton AJ, Vinik AI, Arezzo JC et al (2005) Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28:956–962CrossRefPubMed
27.
Zurück zum Zitat Ewing DJ, Martyn CN, Young RJ, Clarke BF (1985) The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 8:491–498CrossRefPubMed Ewing DJ, Martyn CN, Young RJ, Clarke BF (1985) The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 8:491–498CrossRefPubMed
28.
Zurück zum Zitat Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15:503–510CrossRefPubMed Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15:503–510CrossRefPubMed
29.
Zurück zum Zitat Ishibashi K, Saito Y, Murayama S et al (2010) Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson’s disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging 37:3–11CrossRefPubMed Ishibashi K, Saito Y, Murayama S et al (2010) Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson’s disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging 37:3–11CrossRefPubMed
30.
Zurück zum Zitat Fasano A, Romito LM, Daniele A et al (2010) Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants. Brain 133:2664–2676CrossRefPubMed Fasano A, Romito LM, Daniele A et al (2010) Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants. Brain 133:2664–2676CrossRefPubMed
31.
Zurück zum Zitat York MK, Dulay M, Macias A et al (2008) Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 79:789–795CrossRefPubMed York MK, Dulay M, Macias A et al (2008) Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 79:789–795CrossRefPubMed
32.
Zurück zum Zitat Ceravolo R, Cossu G, Bandettini di Poggio M et al (2013) Neuropathy and levodopa in Parkinson’s disease: evidence from a multicenter study. Mov Disord 28:1391–1397CrossRefPubMed Ceravolo R, Cossu G, Bandettini di Poggio M et al (2013) Neuropathy and levodopa in Parkinson’s disease: evidence from a multicenter study. Mov Disord 28:1391–1397CrossRefPubMed
33.
Zurück zum Zitat Uncini A, Eleopra R, Onofrj M (2015) Polyneuropathy associated with duodenal infusion of levodopa in Parkinson’s disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry 86:490–495CrossRefPubMed Uncini A, Eleopra R, Onofrj M (2015) Polyneuropathy associated with duodenal infusion of levodopa in Parkinson’s disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry 86:490–495CrossRefPubMed
34.
Zurück zum Zitat Lawson RA, Yarnall AJ, Duncan GW et al (2016) Cognitive decline and quality of life in incident Parkinson’s disease: the role of attention. Parkinsonism Relat Disord 27:47–53CrossRefPubMedPubMedCentral Lawson RA, Yarnall AJ, Duncan GW et al (2016) Cognitive decline and quality of life in incident Parkinson’s disease: the role of attention. Parkinsonism Relat Disord 27:47–53CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Merola A, Romagnolo A, Comi C et al (2017) Prevalence and burden of dysautonomia in advanced Parkinson’s disease. Mov Disord 32:796–797CrossRefPubMed Merola A, Romagnolo A, Comi C et al (2017) Prevalence and burden of dysautonomia in advanced Parkinson’s disease. Mov Disord 32:796–797CrossRefPubMed
Metadaten
Titel
Beyond 35 years of Parkinson’s disease: a comprehensive clinical and instrumental assessment
verfasst von
Alberto Romagnolo
Margherita Fabbri
Aristide Merola
Elisa Montanaro
Sara Palermo
Tiziana Martone
Agostino Seresini
Stefano Goldwurm
Mario Giorgio Rizzone
Leonardo Lopiano
Publikationsdatum
26.06.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 9/2018
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-018-8955-z

Weitere Artikel der Ausgabe 9/2018

Journal of Neurology 9/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.